China's Sinopharm COVID-19 vaccine to COVAX in production
BEIJING -- China on June 1 said the first batch of Chinese vaccines supplied to COVAX officially rolled off the production line, which is another important reflection of China's commitment to making its COVID-19 vaccines global public goods with concrete actions.
Foreign Ministry spokesperson Wang Wenbin made the remarks during a daily press briefing after the first batch of the Sinopharm vaccine to COVAX officially rolled off the production line on May 31.
China has always supported COVAX and has decided to provide 10 million COVID-19 vaccine doses to the COVAX cause. Relevant companies are doing their best to ensure vaccine supply, Wang noted.
China will continue to support enterprises to strengthen communication and coordination with the sponsors of COVAX and continue to make China's contribution to the global fight against the pandemic at an early date, the spokesperson said.
- Plan to boost eye care services by 2030
- China sees wider healthcare access as system continues to grow
- China moves to further improve family doctor services
- China targets better health for all by 2030
- China targets average life expectancy of 80 by 2030 in new five-year health plan
- The number of assisted reproductive institutions reaches 645 in China


